CRISPR Therapeutics AG (CRSP) Company Profile & Statistics

CRISPR Therapeutics AG
CRSP
(Nasdaq - US)
Open
47.33
+0.08 (+0.17%)
in:usd•As of: Nov 18, 2024 13:37 UTC -5
Open
47.77
High
48.27
Low
46.71

About CRISPR Therapeutics AG

CEO

Samarth Kulkarni

Headquarters

baarerstrasse 14

zug, v8 ch-6300, switzerland

Auditor

Ernst & Young LLP

Employees

407

Share Holders

Website

www.crisprtx.com

Industry

biotechnology

Sector

health technology

Company Overview

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

CRISPR Therapeutics AG Statistics

Valuation Measures

Market Capitalization ²	4.04B
Enterprise Value	3.81B
Enterprise Value/EBITDA (ttm)	-12.18
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	2.07
Price to Sales (ttm)	19.88
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-118.13%
Profit Margin (ttm)	-15453.78%
Return on Equity (ttm)	-12.15%
Return on Invested Capital (ttm)	-11.66%
Return on Assets (ttm)	-10.35%

Income Statement

Revenue (ttm)	202.83M
Revenue Per Share (ttm)	2.38
Gross Profit (ttm)	202.83M
EBITDA (ttm)³	-313.08M
Net Income Avi to Common (ttm)	-239.59M
Diluted EPS (ttm)	-2.83

Share Statistics

Beta (5Y Monthly)	1.67
52-Week Change	-34.43%
S&P500 52-Week Change	29.66%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	85.35M
Dividend Yield	0.00%
Float ⁴	81.85M
% Held by Insiders	4.10%
% Held by Institutions	69.20%

Balance Sheet

Total Cash (mrq)	1.94B
Total Cash Per Share (mrq)	22.68
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	21.64%
Quick Ratio (mrq)	21.64%
Book Value Per Share (mrq)	22.73

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.09
Free Cash Flow (ytd)	-94.39M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CRISPR Therapeutics AG

Trade With A Regulated Broker